Navigation Links
ViroPharma Announces Completion of Enrollment in Phase 3 Study of Maribavir in Stem Cell Transplant Patients
Date:5/29/2008

e-blind, placebo-controlled, multicenter pivotal Phase 3 study in 681 patients who have undergone allogeneic stem cell transplantation. Following transplantation and transplant engraftment, eligible patients have been randomized to receive maribavir or matching placebo in a 2:1 randomization ratio. All patients will receive maribavir 100 mg BID or placebo for a maximum duration of 12 weeks, and will then be followed for an additional 12 weeks to reach the 6-month post-transplant analyses for regulatory filing purposes. All patients will then be followed for an additional 24 weeks.

Enrolled subjects will undergo testing for CMV infection at least weekly. CMV surveillance includes weekly testing at a central laboratory for the presence of CMV pp65 antigenemia and for the presence of CMV DNA in plasma using a polymerase chain reaction (PCR). If CMV infection is detected during the study drug administration period (or if CMV organ disease is diagnosed), study drug will be discontinued and the subject will be managed according to standard CMV treatment practices at the transplant center.

The primary efficacy endpoint will be the incidence of CMV disease within six months post-transplant, which is predicted to be approximately nine percent in the placebo (current standard of care) arm based on data from the Phase 2 study, data from published literature, and information from transplant center databases. Following extensive dialogue with FDA, a number of key secondary endpoints associated with CMV infection have been identified and assessment of these endpoints will be essential in assessing the clinical benefit of maribavir. These key secondary endpoints include incidence of initiation of preemptive anti-CMV therapy, incidence of graft-versus-host disease, mortality and CMV disease-free survival.

About maribavir

Maribavir is a potent and selective, orally bioavailable Phase 3 antiviral drug with a unique mechanism of action against cytomegalovir
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. ViroPharma Announces Discontinuation of HCV-796 Development
2. ViroPharma to Release 2008 First Quarter Financial Results on April 30, 2008
3. ViroPharma To Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
4. ViroPharma to Present at the Natixis Bleichroeder Conference
5. ViroPharma to Present at Three Upcoming Healthcare Conferences
6. Strativa Pharmaceuticals Announces Preliminary Results from ONCONASE(R) Phase IIIb Clinical Trial
7. InterMune Announces Start of 14-Day Triple Combination Study of ITMN-191 in Patients With Chronic Hepatitis C
8. GlaxoSmithKline Announces New Drug Application and Phase III Results for Rezonic(TM)/Zunrisa(TM) (Casopitant)
9. Genmab Announces Updates on Phase III Cancer Studies
10. Kiadis Pharma Announces Collaboration With the Julius Maximilians University of Wurzburg, Germany
11. Alfacell Corporation Announces Preliminary Results From ONCONASE(R) Phase IIIb Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... CHESTERBROOK, Pa. , July 31, 2014   ... a fully integrated specialty biopharmaceutical company, today announced that ... of 2014 on Thursday, August 7, 2014 before the ... will conduct a conference call that day at 8:30 ... second quarter of 2014. The presentation slides to be ...
(Date:7/31/2014)... -- Rock Creek Pharmaceuticals, Inc., (NASDAQ: RCPI ... of its lead molecule, Anatabine Citrate, in ... Clinical, The Translational Pharmaceutics Company, based in the ... early development programs. The Company expects to ... of the third quarter with the Medicines Healthcare products ...
(Date:7/31/2014)... , July 31, 2014  Decision Resources Group ... market intelligence product Marketrack to now include ChinaTrack; the ... device landscape in an interactive dashboard providing detailed brand-level ... volumes at a hospital level. Other key ... Updated data feed: In addition to end-user surveys of ...
Breaking Medicine Technology:Auxilium Pharmaceuticals, Inc. To Announce Second Quarter 2014 Results On August 7, 2014 2Auxilium Pharmaceuticals, Inc. To Announce Second Quarter 2014 Results On August 7, 2014 3Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical for its early development programs 2Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical for its early development programs 3Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical for its early development programs 4Decision Resources Group Announces First Medical Device Account Targeting Tool in China 2
... , HOPKINTON, Mass., Nov. 2 Caliper Life Sciences, Inc. ... tools, presented at a training session for reviewers from the ... of the LabChip GX platform for high throughput screening and ... accept the FDA,s invitation to present our LabChip platform to ...
... This week begins American Diabetes Month® - a ... the launch of a new campaign by the American Diabetes ... and one of its National Strategic Partners, Liberty Medical Supply, ... give diabetes patients practical tips and advice for living with ...
Cached Medicine Technology:Caliper Life Sciences Presents LabChip(R) Platform to the U.S. Food and Drug Administration 2Educational Video Series Released for American Diabetes Month 2Educational Video Series Released for American Diabetes Month 3Educational Video Series Released for American Diabetes Month 4
(Date:8/1/2014)... 1, 2014 (HealthDay News) -- Patients with the progressive, ... (COPD) have a new weapon to battle the disease, ... The agency approved a new treatment, an inhaled ... leading killer of Americans. COPD, which is often linked ... bronchitis and emphysema. Patients with COPD may ...
(Date:8/1/2014)... According to new market research ... North America, Europe, & ROW), by Vehicle Type ... (Gasoline & Diesel), by After-Treatment Device (DPF, DOC, ... Forecasts to 2019", defines and segments the global ... major countries in all the regions, and estimates ...
(Date:8/1/2014)... NY (PRWEB) August 01, 2014 ... industry have benefited from innovative technologies that have ... resemble a patient's tooth color. Moreover, the burgeoning ... due to age-related tooth ailments. Due to long-term ... many elderly individuals have demanded dental fillings, veneers ...
(Date:8/1/2014)... (PRWEB) August 01, 2014 ... Market Outlook to 2020", provides key market ... market. The report provides value, in millions ... average prices (in US dollars) within market ... Ultrasonic Generators and Argon Plasma Coagulation Generators. ...
(Date:8/1/2014)... Kathleen Doheny HealthDay Reporter ... control pills containing high doses of estrogen, along with ... cancer in women under 50, new preliminary research ... lead researcher Elisabeth Beaber, a staff scientist at the ... these formulations increase breast cancer risk while other formulations ...
Breaking Medicine News(10 mins):Health News:FDA Approves New Treatment for People With COPD 2Health News:Automotive Exhaust Systems Market Will Be $33,379.7 Million by 2019 – New Report by MarketsandMarkets 2Health News:Automotive Exhaust Systems Market Will Be $33,379.7 Million by 2019 – New Report by MarketsandMarkets 3Health News:Automotive Exhaust Systems Market Will Be $33,379.7 Million by 2019 – New Report by MarketsandMarkets 4Health News:Cosmetic Dentists in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Cosmetic Dentists in the US Industry Market Research Report from IBISWorld Has Been Updated 3Health News:United Kingdom Surgical Generators Market Size, Share, Analysis, Trends and Forecasts 2020 2Health News:United Kingdom Surgical Generators Market Size, Share, Analysis, Trends and Forecasts 2020 3Health News:Some Birth Control Pills May Up Breast Cancer Risk 2Health News:Some Birth Control Pills May Up Breast Cancer Risk 3
... case of virgin birth in cartilaginous fish, after busting the mystery ... had only female sharks which had no contact with a male ... at Omaha's Henry Doorly Zoo, in the US, in December 2001 ... the female sharks in the aquarium. ,Female sharks have ...
... are in favour of a ban on smoking in workplaces ... ,Some 88 percent of citizens in the European Union ... a study by the European Commission, the bloc's executive arm. ... support for anti-tobacco policies could help make European public and ...
... the concerns of developing countries like Indonesia, the Unjted Nations ... efforts would be made to ensure "fair and equitable distribution ... of a pandemic." ,At the same time the ... WHO. ,A resolution on those lines ...
... a meeting of the U.N. General Assembly to review the ... it is possible to halt and reverse the spread of ... worldwide. ,U.N. member countries last year renewed pledges ... prevention, treatment and care services by 2010. In addition, one ...
... shown that a compound extracted from a plant from the ... and block its effect on the brain. ... Drug Abuse found that upon administration of the plant extract, ... tetrahydrocannabinol (THC), an active compound in marijuana. The treatment also ...
... in Vietnam confirmed Wednesday the possibility that a resident of ... contracted the lethal H5N1 strain of the bird flu virus, ... ,A fresh outbreak of bird flu has hit five provinces ... strain after being hospitalized in serious condition. ...
Cached Medicine News:Health News:WHO Announces Deal on Sharing Bird Flu Virus 2Health News:U.N. Secretary-General Ban Renews Goal To Reverse Spread of HIV by 2015 2Health News:Compound Present in Plant may Help to Curb Craving for Cannabis 2
... Instruments incorporate a layered design unique in ... monitored to prevent stray electrosurgical burns along ... insulation failure or capacitive coupling; a well-documented ... into all AEM Instruments provides a neutral ...
... Instruments incorporate a layered design unique in ... monitored to prevent stray electrosurgical burns along ... insulation failure or capacitive coupling; a well-documented ... into all AEM Instruments provides a neutral ...
... The 5mm AEM Laparoscopic Instruments incorporate a ... Instruments are shielded and monitored to prevent ... the instrument caused by insulation failure or ... The protective shield built into all AEM ...
... Instruments incorporate a layered design unique in ... monitored to prevent stray electrosurgical burns along ... insulation failure or capacitive coupling; a well-documented ... into all AEM Instruments provides a neutral ...
Medicine Products: